MRI评估结直肠癌肝转移瘤化疗疗效的研究进展

Progress of MRI in assessing the efficacy of chemotherapy for colorectal liver metastases

结直肠癌(colorectal cancer,CRC)是世界上第三位最常见的恶性肿瘤,也是导致癌症相关死亡的主要原因。肝转移是CRC最常见的远处转移,与不良预后密切相关。早期精准预测疗效对患者的预后至关重要。近年来,出现了一些基于MRI评估疗效的方法,包括功能MRI(functional magnetic resonance imaging,fMRI)和基于MRI的影像组学等。本文就各种MRI技术在结直肠癌肝转移瘤(colorectal liver metastasis,CRLM)疗效评估中的优劣进行综述,同时叙述了生物标志物在评估CRLM患者预后方面的应用,为临床制订个体化治疗方案提供可靠依据,为科研工作提供新的思路。

Colorectal cancer(CRC)is the third most common malignancy in the world and the leading cause of cancer-related deaths.Liver metastasis is the most common distant metastasis of CRC,which is closely related to poor prognosis.Early and accurate prediction of curative effect is very important for the prognosis of patients.In recent years,there have been some MRI-based methods to evaluate the efficacy,including functional magnetic resonance imaging(fMRI),MRI-based imagomics and so on.This article reviews the advantages and disadvantages of the efficacy evaluation methods for colorectal liver metastasis(CRLM),and describes the application of biomarkers in evaluating the prognosis of CRLM patients,provides a reliable basis for clinical individualized treatment,and provides new ideas for scientific research.